| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences [H. I., K. N., M. O., E. J. C., Y. N., K. Su.], and Second Department of Oral and Maxillofacial Surgery, Faculty of Dentistry [H. I., K. Sh.], Kyushu University, Fukuoka 812-0054, and Division of Gene Therapy Science, School of Medicine, Osaka University, Osaka [Y. K.], Japan
Vasculature development is thought to be an important aspect in the
growth and metastasis of solid tumors. Among the angiogenic factors
produced by tumor cells, vascular endothelial growth factor is
considered to be the most potent and pathologically important. The
synthesis of this growth factor has been shown to be modulated through
Sp1 function following stimulation by tumor necrosis factor
(TNF-
). Oligodeoxynucleotides (ODNs) were synthesized with
either the consensus sequence for Sp1 binding (Sp1 decoy ODNs) or a
mutated form of this sequence (mt-Sp1 decoy ODNs). Using the
hemagglutinating virus of Japan (HVJ)-liposome method, we transferred
these ODNs into cultured cancer cells (A549 and U251 cells). The
TNF-
-mediated expression of both VEGF and transforming growth factor
ß1 and tissue factor (TF) by the cancer cells could be
simultaneously suppressed to less than 30% by transfection of Sp1
decoy ODNs but not by mt-Sp1 decoy ODNs. In addition, in
vitro invasiveness, synthesis of mRNA for urokinase-type
plasminogen activator, and cell proliferation of both cell lines were
also inhibited to 40% by the transfection of only Sp1 decoy ODNs.
These results suggested that the Sp1 decoy strategy would be effective
for regulating tumor growth by simultaneously reducing cancer cell
(a) angiogenic growth factor expression,
(b) proliferation, and (c) invasiveness.
This article has been cited by other articles:
![]() |
M. Ganapathy, R. Ghosh, X. Jianping, X. Zhang, R. Bedolla, J. Schoolfield, I-T. Yeh, D. A. Troyer, A. F. Olumi, and A. P. Kumar Involvement of FLIP in 2-Methoxyestradiol-Induced Tumor Regression in Transgenic Adenocarcinoma of Mouse Prostate Model Clin. Cancer Res., March 1, 2009; 15(5): 1601 - 1611. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Y. Jiang, B. A. Woda, B. F. Banner, G. F. Whalen, K. A. Dresser, and D. Lu Sp1, a New Biomarker That Identifies a Subset of Aggressive Pancreatic Ductal Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1648 - 1652. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W. Y. Lui, A. L. Boehm, P. Koppikar, R. J. Leeman, D. Johnson, M. Ogagan, E. Childs, M. Freilino, and J. R. Grandis Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting Signal Transducer and Activator of Transcription (STAT) 3: The Role of STAT1 Mol. Pharmacol., May 1, 2007; 71(5): 1435 - 1443. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Jungert, A. Buck, G. v. Wichert, G. Adler, A. Konig, M. Buchholz, T. M. Gress, and V. Ellenrieder Sp1 Is Required for Transforming Growth Factor-{beta}-Induced Mesenchymal Transition and Migration in Pancreatic Cancer Cells Cancer Res., February 15, 2007; 67(4): 1563 - 1570. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kanai, D. Wei, Q. Li, Z. Jia, J. Ajani, X. Le, J. Yao, and K. Xie Loss of kruppel-like factor 4 expression contributes to sp1 overexpression and human gastric cancer development and progression. Clin. Cancer Res., November 1, 2006; 12(21): 6395 - 6402. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Abdelrahim, C. H. Baker, J. L. Abbruzzese, and S. Safe Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst, June 21, 2006; 98(12): 855 - 868. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Albertini, A. Jain, S. Vignati, S. Napoli, A. Rinaldi, I. Kwee, M. Nur-e-Alam, J. Bergant, F. Bertoni, G. M. Carbone, et al. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res., January 1, 2006; 34(6): 1721 - 1734. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Pages and J. Pouyssegur Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors Cardiovasc Res, February 15, 2005; 65(3): 564 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Lou, S. O'Reilly, H. Liang, V. M. Maher, S. D. Sleight, and J. J. McCormick Down-Regulation of Overexpressed Sp1 Protein in Human Fibrosarcoma Cell Lines Inhibits Tumor Formation Cancer Res., February 1, 2005; 65(3): 1007 - 1017. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Kunz, M. R. Jadus, G. D. Kukes, F. Kramer, V. N. Nguyen, and S. A. Sasse Intrapleural Injection of Transforming Growth Factor-{beta} Antibody Inhibits Pleural Fibrosis in Empyema Chest, November 1, 2004; 126(5): 1636 - 1644. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sato and K. Furukawa Transcriptional Regulation of the Human {beta}-1,4-Galactosyltransferase V Gene in Cancer Cells: ESSENTIAL ROLE OF TRANSCRIPTION FACTOR Sp1 J. Biol. Chem., September 17, 2004; 279(38): 39574 - 39583. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wei, L. Wang, Y. He, H. Q. Xiong, J. L. Abbruzzese, and K. Xie Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity Cancer Res., March 15, 2004; 64(6): 2030 - 2038. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, D. Wei, S. Huang, Z. Peng, X. Le, T. T. Wu, J. Yao, J. Ajani, and K. Xie Transcription Factor Sp1 Expression Is a Significant Predictor of Survival in Human Gastric Cancer Clin. Cancer Res., December 15, 2003; 9(17): 6371 - 6380. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tsuchiya, M. Sakamoto, J. Yasuda, M. Chuma, T. Ohta, M. Ohki, T. Yasugi, Y. Taketani, and S. Hirohashi Expression Profiling in Ovarian Clear Cell Carcinoma: Identification of Hepatocyte Nuclear Factor-1{beta} as a Molecular Marker and a Possible Molecular Target for Therapy of Ovarian Clear Cell Carcinoma Am. J. Pathol., December 1, 2003; 163(6): 2503 - 2512. [Abstract] [Full Text] |
||||
![]() |
R L Stephen, J E Crabtree, T Yoshimura, C L Clayton, M F Dixon, and P A Robinson Increased zinc finger protein zFOC1 transcripts in gastric cancer compared with normal gastric tissue Mol. Pathol., June 1, 2003; 56(3): 167 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tang, D. Zhang, L. Fallavollita, and P. Brodt Vascular Endothelial Growth Factor C Expression and Lymph Node Metastasis Are Regulated by the Type I Insulin-like Growth Factor Receptor Cancer Res., March 15, 2003; 63(6): 1166 - 1171. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Borgatti, I. Lampronti, A. Romanelli, C. Pedone, M. Saviano, N. Bianchi, C. Mischiati, and R. Gambari Transcription Factor Decoy Molecules Based on a Peptide Nucleic Acid (PNA)-DNA Chimera Mimicking Sp1 Binding Sites J. Biol. Chem., February 21, 2003; 278(9): 7500 - 7509. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Abdelrahim, I. Samudio, R. Smith III, R. Burghardt, and S. Safe Small Inhibitory RNA Duplexes for Sp1 mRNA Block Basal and Estrogen-induced Gene Expression and Cell Cycle Progression in MCF-7 Breast Cancer Cells J. Biol. Chem., August 2, 2002; 277(32): 28815 - 28822. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |